Scienture Holdings, Inc. (SCNX) AI Stock Analysis

Scienture Holdings, Inc. operates as a pharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company is developing SCN-102, an oral liquid formulation of losartan potassium in phase 1 for hypertension, diabetic nephropathy, and reducing stroke risk in patients with hypertension and left ventricular hypertrophy. Its pipeline also includes SCN-104, a multi-dose dihydroergotamine mesylate injection pen; SCN-106, a thrombolytic agent that binds to fibrin in clots; and SCN-107, a long-acting injection suspension of a non-opioid analgesic for postsurgical analgesia. Scienture is headquartered in Commack, New York, and employs 4 people.

Scienture has experienced significant top-line volatility, with a 5-year revenue CAGR of -52.1% from FY2020 to FY2025. Annual revenue decreased from $10.3M in FY2022 to $1.4M in FY2023, and fell 90.0% to $136,643 in FY2024. In FY2025, revenue rose 215.9% to $431,609, supported by a gross margin of 76.8%, though the operating margin was -3763.8% and net income was -$41.5M. For the latest quarter ended June 30, 2026, quarterly revenue growth was 449.1% year-over-year, bringing trailing twelve month revenue to $821,315 with an operating margin of -785.6% and diluted eps of -$52.75.

As of June 30, 2026, Scienture held $8.2M in cash and short-term investments and total debt of $10.7M, resulting in net debt of $2.5M. The company reported total assets of $87.7M and shareholders' equity of $64.1M, with a current ratio of 3.04 and a debt-to-equity ratio of 0.17. In FY2025, operating cash flow was -$13.4M and free cash flow was -$13.4M, with capital expenditures of $3. Over five years, the company expanded its share count by 191.4%.

Scienture carries a market cap of $5.5M and an enterprise value of $14.4M. Its forward P/E multiple is 21.8x, compared to 17.3x for the median of its US-listed Healthcare peers. Its price-to-sales ratio stands at 6.7x, higher than the peer median of 4.1x, while its price-to-book ratio is 0.2x. Over the past year, SCNX shares dropped 77.2%, while the SPY S&P 500 benchmark gained 16.8%. Over five years, the stock returned -99.7% against an 83.0% return for the S&P 500.

Wall Street coverage on Scienture is limited, with 1 Buy rating and 0 Hold or Sell ratings. The mean price target is $37.50, representing upside of 1016.1% compared to the last close of $3.36 on October 16, 2026. For the current fiscal year ending December 31, 2026, the analyst consensus projects revenue of $4.8M and an EPS estimate of -$5.75. Scienture has beaten EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of Scienture Holdings, Inc. (SCNX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SCNX income statement, SCNX balance sheet, SCNX key metrics, SCNX analyst forecast, SCNX chart. See the SCNX stock overview for the latest quote and news.